Understanding the Nilotinib trials
The results of a Phase II trial on the safety of nilotinib in people with Parkinson’s has shown ambiguous biochemical results and a greater number of adverse events in the treated groups.
The results of a Phase II trial on the safety of nilotinib in people with Parkinson’s has shown ambiguous biochemical results and a greater number of adverse events in the treated groups.
A new preclinical study has shown that LRRK2 inhibition in an animal model of Parkinson’s can improve lysosomal health and reduce alpha synuclein accumulation in dopaminergic neurons.
A prostrate drug (Terazosin) has been shown to exert neuroprotective effects in animal models.
AUDIO VERSION AVAILABLE.
Focus ultrasound (FUS) is a promising new area to improve delivery of drugs and neurotrophic factors
New animal model of PD shows misfolded alpha synuclein can spread from gut to brain.
AUDIO VERSION AVAILABLE.